14:29 , Mar 19, 2019 |  BC Innovations  |  Distillery Therapeutics

Pan-ALDH1A inhibitor for ovarian cancer

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer In vitro , cell culture and mouse studies identified a pan-ALDH1A inhibitor that could help treat ovarian cancer. Chemical synthesis and in vitro testing of diethylaminobenzaldehyde analogs yielded a...
22:59 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest the generic antibiotic nifuroxazide could help treat melanoma. In two human metastatic melanoma cell lines, nifuroxazide plus the BRAF inhibitor Zelboraf vemurafenib and the MEK inhibitor Mekinist...
07:00 , Sep 22, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Aldehyde dehydrogenase 1 family member A1 (ALDH1A1); cytochrome P450 26A1 (CYP26A1; CP26)

Cancer INDICATION: Colorectal cancer Patient sample and mouse studies suggest enhancing all-trans retinoic acid (ATRA) levels could help treat colorectal cancer. In tumor samples from colorectal cancer patients, levels of ALDH1A1 - which participates in...
07:00 , Oct 11, 2012 |  BC Innovations  |  Cover Story

Ember: warming up to brown fat

A team led by Boston-area researchers has shown that inhibiting a cation channel dubbed TRPV4 induced white fat cells to behave like brown fat, thereby protecting mice from diet-induced obesity and insulin resistance. 1 Ember...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Company News

Ember Therapeutics, Brigham and Women's Hospital, Dana-Farber Cancer Institute deal

Ember received exclusive options to IP for three targets related to its brown fat small molecule drug discovery program. Brigham and Women's Hospital gave the company an option for IP surrounding aldehyde dehydrogenase 1 family...
01:00 , Oct 5, 2012 |  BC Extra  |  Company News

Ember receives options for brown fat IP

Ember Therapeutics Inc. (Boston, Mass.) received exclusive options to IP for three targets related to its brown fat small molecule drug discovery program. Brigham and Women's Hospital gave the company an option for IP surrounding...
07:00 , May 31, 2012 |  BC Innovations  |  Targets & Mechanisms

Going to BAT

Two teams are reporting new targets for inducing the conversion of white fat to a brown-like phenotype, or boosting the activity of existing brown fat, that could help treat obesity and related metabolic diseases. A...
07:00 , May 24, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity Aldehyde dehydrogenase 1 family member A1 (ALDH1A1) Mice and human tissue studies suggest antagonizing ALDH1A1 could help treat obesity and type 2...
07:00 , Apr 2, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Asthma Matrix metallopeptidase 7 (matrilysin, uterine) (MMP7); IL-25; aldehyde dehydrogenase 1 family, member A1 (ALDH1A1; RALDH1A1) Studies in cell culture and...
02:42 , Dec 8, 2007 |  BC Extra  |  Clinical News

ALDH1A1: a marker for breast cancer stem cells

Researchers from the University of Michigan and colleagues reported in Cell Stem Cell that increased aldehyde dehydrogenase 1 family member A1 (ALDH1A1) activity is a biomarker of breast carcinoma stem cells. Cells with increased ALDH1...